During 1997 extensive scientific discussion continued on the revision of existing notes for guidance concerning vaccines (requirements for influenza and combination vaccines), medicinal products derived from blood and plasma (clotting factor concentrates, albumin and immunoglobulin) and issues on the potential risk of transmission of spongiform encephalopathy via medicinal products.